首页> 美国卫生研究院文献>The Journal of Pharmacology and Experimental Therapeutics >Effects of Ketamine and Ketamine Metabolites on Evoked Striatal Dopamine Release Dopamine Receptors and Monoamine Transporters
【2h】

Effects of Ketamine and Ketamine Metabolites on Evoked Striatal Dopamine Release Dopamine Receptors and Monoamine Transporters

机译:氯胺酮和氯胺酮代谢物对诱发纹状体多巴胺释放多巴胺受体和单胺转运蛋白的影响

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Following administration at subanesthetic doses, (R,S)-ketamine (ketamine) induces rapid and robust relief from symptoms of depression in treatment-refractory depressed patients. Previous studies suggest that ketamine’s antidepressant properties involve enhancement of dopamine (DA) neurotransmission. Ketamine is rapidly metabolized to (2S,6S)- and (2R,6R)-hydroxynorketamine (HNK), which have antidepressant actions independent of N-methyl-d-aspartate glutamate receptor inhibition. These antidepressant actions of (2S,6S;2R,6R)-HNK, or other metabolites, as well as ketamine’s side effects, including abuse potential, may be related to direct effects on components of the dopaminergic (DAergic) system. Here, brain and blood distribution/clearance and pharmacodynamic analyses at DA receptors (D1–D5) and the DA, norepinephrine, and serotonin transporters were assessed for ketamine and its major metabolites (norketamine, dehydronorketamine, and HNKs). Additionally, we measured electrically evoked mesolimbic DA release and decay using fast-scan cyclic voltammetry following acute administration of subanesthetic doses of ketamine (2, 10, and 50 mg/kg, i.p.). Following ketamine injection, ketamine, norketamine, and multiple hydroxynorketamines were detected in the plasma and brain of mice. Dehydronorketamine was detectable in plasma, but concentrations were below detectable limits in the brain. Ketamine did not alter the magnitude or kinetics of evoked DA release in the nucleus accumbens in anesthetized mice. Neither ketamine’s enantiomers nor its metabolites had affinity for DA receptors or the DA, noradrenaline, and serotonin transporters (up to 10 μM). These results suggest that neither the side effects nor antidepressant actions of ketamine or ketamine metabolites are associated with direct effects on mesolimbic DAergic neurotransmission. Previously observed in vivo changes in DAergic neurotransmission following ketamine administration are likely indirect.
机译:在亚麻醉剂量下给药后,(R,S)-氯胺酮(氯胺酮)可以使治疗难治性抑郁症患者的抑郁症状迅速而稳定地缓解。先前的研究表明,氯胺酮的抗抑郁特性涉及多巴胺(DA)神经传递的增强。氯胺酮迅速代谢为(2S,6S)-和(2R,6R)-羟基降甲胺(HNK),其具有独立于N-甲基-d-天冬氨酸谷氨酸受体抑制的抗抑郁作用。 (2S,6S; 2R,6R)-HNK或其他代谢物的这些抗抑郁作用以及氯胺酮的副作用(包括滥用可能性),可能与对多巴胺能(DAergic)系统成分的直接影响有关。在这里,评估了氯胺酮及其主要代谢产物(去甲胺,去氢去甲胺和HNKs)在DA受体(D1-D5)和DA,去甲肾上腺素和5-羟色胺转运蛋白上的脑和血液分布/清除率和药效学分析。另外,在亚麻醉剂量的氯胺酮(2、10和50 mg / kg,腹腔注射)急性给药后,我们使用快速扫描循环伏安法测量了电诱发的中脑边缘DA的释放和衰减。注射氯胺酮后,在小鼠的血浆和脑中检测到氯胺酮,去甲氯胺酮和多种羟基去甲氯胺酮。血浆中可检测到脱氢降氯胺酮,但脑中的浓度低于可检测的极限。氯胺酮未改变麻醉小鼠伏隔核中诱发的DA释放的幅度或动力学。氯胺酮的对映异构体或其代谢产物均不对DA受体或DA,去甲肾上腺素和血清素转运蛋白(最高10μM)具有亲和力。这些结果表明,氯胺酮或氯胺酮代谢产物的副作用或抗抑郁作用均与中脑边缘DA能神经传递的直接作用无关。氯胺酮给药后先前观察到的DA能神经传递的体内变化可能是间接的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号